Investigational drug · Phase 2
Daxdilimab
Also called: HZN-7734
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Idiopathic Inflammatory Myositis.
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 25, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
6
Any phase or sponsor naming "Daxdilimab"
First trial start
2023
Dec 4, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Daxdilimab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Idiopathic Inflammatory Myositis
Largest trials
Live from ClinicalTrials.gov: studies naming "Daxdilimab" as an intervention, largest first.
- Study of VIB7734 for the Treatment of Moderate to Severely Active SLEPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT04925934 · 214 participants · Start May 28, 2021 · Primary completion May 16, 2023
Drug: VIB7734 · For: Lupus Erythematosus, Systemic
Sites: Upland, California; Clearwater, Florida; Ormond Beach, Florida · 67 sites in all
AmgenAmgen (AMGN)
NCT05430854 · 155 participants · Start Jun 1, 2022 · Primary completion Oct 31, 2023
Drug: Daxdilimab · For: Systemic Lupus Erythematosus
Sites: Upland, California; Clearwater, Florida; Ormond Beach, Florida · 52 sites in all
AmgenAmgen (AMGN)
NCT05591222 · 72 participants · Start Dec 29, 2022 · Primary completion May 8, 2025
Drug: Placebo; Daxdilimab · For: Discoid Lupus Erythematosus
Sites: North Little Rock, Arkansas; Beverly Hills, California; Fremont, California · 68 sites in all
AmgenAmgen (AMGN)
NCT05368103 · 30 participants · Start Apr 27, 2022 · Primary completion Aug 7, 2023
Drug: Daxdilimab · For: Alopecia Areata
Sites: Hot Springs, Arkansas; Fountain Valley, California; Tampa, Florida · 13 sites in all
- Study of Daxdilimab (HZN-7734) in Participants With Active Proliferative Lupus Nephritis (LN)Terminated
AmgenAmgen (AMGN)
NCT05540665 · 19 participants · Start Apr 26, 2023 · Primary completion Jan 4, 2024
Drug: Daxdilimab; Daxdilimab and 1 more · For: Lupus Nephritis
Sites: Birmingham, Alabama; San Dimas, California; Syracuse, New York · 52 sites in all
AmgenAmgen (AMGN)
NCT05669014 · 12 participants · Start Dec 4, 2023 · Primary completion Jul 2, 2025
Drug: Daxdilimab; Placebo · For: Idiopathic Inflammatory Myositis
Sites: Anaheim, California; Juiz de Fora, Brazil; Porto Alegre, Brazil · 9 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Modern Therapies for Discoid Lupus Erythematosus: A Narrative Review.
Jonnalagadda A, Richmond RL, Pathak GN, et al. · Dermatol Ther (Heidelb) 2026
- [Translated article] RF - New Treatments in Cutaneous Lupus Erythematosus: Current and Future Perspectives.
Mansilla-Polo M, Martín-Torregrosa D, Botella-Estrada R · Actas Dermosifiliogr 2025
- An Integrative Mechanistic Model of Type 1 IFN-Mediated Inflammation in Systemic Lupus Erythematosus.
Volkova A, Sokolov V, Tettamanti F, et al. · CPT Pharmacometrics Syst Pharmacol 2025
- A focused report on IFN-1 targeted therapies for lupus erythematosus.
Bhatt A, Gupta P, Furie R, et al. · Expert Opin Investig Drugs 2025
- Emerging immunotherapeutic strategies for cutaneous lupus erythematosus: an overview of recent phase 2 and 3 clinical trials.
Lim D, Kleitsch J, Werth VP · Expert Opin Emerg Drugs 2023
- Emerging drugs for the treatment of alopecia areata.
Ramírez-Marín HA, Tosti A · Expert Opin Emerg Drugs 2022
Also in development for Idiopathic Inflammatory Myositis
- PF-08154225Phase 21 trial
Pfizer · Systemic Lupus Erythematosus, Rheumatoid Arthritis, Idiopathic Inflammatory Myositis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Amgen.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.